ASAri Winasti Satyagraha

Ari Winasti Satyagraha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ari Winasti Satyagraha has a total of 274 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Applying Diagnostic Network Optimisation analysis to inform the introduction of G6PD testing into Indonesia for improved treatment of relapsing malaria

    by Karina Dian Lestari, Ihsan Fadilah, Illene Nanine, Hellen Dewi Prameswari, Minerva Theodora, Bayu Kurnia, Hermawan Susanto, Ratih Ketana Hapsari, Dimas Prayoga, Aditya Kris Nugroho, et al.

    Background: Radical cure for P. vivax and P. ovale malaria using 8-aminoquinoline drugs primaquine or tafenoquine can prevent relapse, but requires glucose-6-phosphate dehydrogenase (G6PD) screening due to the risk of haemolysis in G6PD-deficient individuals. This study aimed to provide an evidence-based framework to inform the optimal allocation and referral networks for G6PD testing devices in Indonesia. Methods: A diagnostic network optimisation (DNO) analysis using OptiDx was conducted across eight districts in Sumba, North Sumatra, and Central Java, representing high-, moderate-, and low-transmission settings. The maximum annual number of malaria cases from surveillance data between 2019 and 2022 was used as a proxy for testing demand. In baseline scenario, all public health facilities were equipped with G6PD testing devices. In referral scenario, devices were allocated only to selected facilities, with a maximum sample transport distance of 15 kilometres and sample delivery scheduled three times per week. Model outputs were reviewed with the National Malaria Control Programme (NMCP) to identify the optimal scenario, considering factors including implementation cost and accessibility. Results: Equipping 39% (30/76) of facilities in Sumba with G6PD testing devices could reduce total costs by nearly 30% in the first year and approximately 20% in subsequent years compared with the baseline, although the average referral distance increased from 4.48 kilometres to 9.8 kilometres. In North Sumatra, deploying 15 of 68 devices (19%) could reduce total costs by almost 60% in the first year and approximately 15% thereafter. Two health facilities (Puskesmas Padewatu in Sumba and Abdul Manan Hospital in North Sumatra) could experience workload increase exceeding 400 hours annually as referral facilities. In Purworejo, a single device placed at Puskesmas Mranti could enable on-site diagnosis for 56% of patients. Interpretation: The findings demonstrated that DNO can identify cost-efficient and equitable G6PD testing strategies to support safe radical cure and accelerate malaria elimination.

  • The case for routine neonatal glucose-6-phosphate dehydrogenase (G6PD) screening in Indonesia

    by Ari W. Satyagraha, Arkasha Sadhewa, Astrid Dian Pratiwi, R. Adhi Teguh Perma Iskandar

  • Open Access

    Profile of red blood cell disorders among healthy schoolchildren in the low malaria-endemic region in Indonesia

    by Ayodhia Pitaloka Pasaribu, Illene Nanine, Framita Ainur, Vincent Jimanto, Azkarunia Pasidiaz Hutagalung, Lydia Visita Panggalo, Devin, Olga Rasiyanti Siregar, Beby Syofiani Hasibuan, Fahmi Fahmi, et al.

    Red blood cell (RBC) disorders arose as an advantageous evolutionary response to malaria infections. In a heterozygous condition, such as in Southeast Asian Ovalocytosis (SAO), hosts are protected against severe malaria. In malaria-endemic regions, RBC disorders are presumed to be highly prevalent. Tanjung Leidong, a moderately endemic area in North Sumatra (API 1.13 in 2024), lacks comprehensive data on RBC disorder prevalence beyond G6PD deficiency. Therefore, this study aims to characterize the RBC disorders in this region as well as to characterize the anemia status in children living in Tanjung Leidong. Schoolers attending D. I. Panjaitan elementary to high school were recruited and screened for malaria by microscopy and G6PD deficiency using the STANDARD G6PD Assay. The DNA of the participants was also extracted to be genotyped for SAO, Hemoglobin E (HbE), and α-thalassemia. Exclusively, G6PD-deficient DNA samples were genotyped further to determine variants. The proportion of G6PD deficiency, SAO, HbE, α-thalassemia one-gene deletion, and two-gene deletion were 0.90%, 0.90%, 2.40%, 6.26%, and 0.30%, respectively. Anemia prevalence was approximately 14%, and RBC disorders were observed across children with normal to obese BMI. No malaria infections were detected by microscopy. The predominance of asymptomatic RBC disorders highlights that they are protective against malaria infection, although their protective role against malaria could not be directly assessed in this study. Both nutritional and genetic factors are found to contribute to anemia in this cohort. These findings underscore the importance of integrated screening strategies for RBC disorders and anemia in malaria-endemic settings.

  • Open Access

    G6PD deficiency in Indonesia: a systematic review and update of prevalence and variant maps in the context of malaria elimination

    by Arkasha Sadhewa, Lydia Visita Panggalo, Illene Nanine, Ihsan Fadilah, Jontari Hutagalung, Enny Kenangalem, Prisca Cynthia Limardi, Safarina G. Malik, Rintis Noviyanti, Ayodhia Pitaloka Pasaribu, et al.


  • Detection and molecular characterization of dengue among patients suspected of having malaria in Timika, Central Papua, Indonesia

    by Leily Trianty, Bunga Rana, Mercy Egrina Adiniko, Marsha Sinditia Santoso, Agatha Mia Puspitasari, Ristya Amalia, Pak Prayoga, Jeanne Rini Poespoprodjo, Enny Kenangalem, Dionisius Denis, et al.

    Background: Dengue and malaria are major public health problems in Indonesia. Dengue is hyperendemic nationwide, while malaria remains endemic in specific regions, especially in eastern Indonesia. Timika in Central Papua province is a highly malaria-endemic area; however, this city is historically known as a low endemic area for dengue. With the increasing incidence of dengue in Papua, this study aimed to assess dengue prevalence, possible co-infection and to molecularly characterize the dengue virus (DENV) in patients suspected of having malaria. Methods: Archived samples of patients suspected of having malaria were screened for dengue using RT-PCR. Dengue serological and antigen detection was performed and whole genome sequencing was employed to determine the genetic characteristics of viruses. Detection of other arboviruses was also performed. Results: Among 119 patients, 30 (25.2%) were positive for dengue. Most samples (n=29) were infected by DENV-3, while one was positive for DENV-2. Dengue and malaria co-infections were found in six patients. Phylogenetic analysis classified DENV-2 as the Cosmopolitan genotype that is closely related to strains from the Indonesian city of Makassar, while DENV-3 was classified as Genotype I, which is closely related to a strain from Singapore. Conclusions: Dengue significantly contributes to febrile illness among patients suspected of having malaria in Timika, Central Papua. Virus importation from surrounding regions is likely to contribute to the dispersion of DENV into eastern parts of Indonesia. Our findings reveal the underestimation of this viral disease in a highly malaria-endemic area.

  • Open Access

    Case Series of Primaquine-Induced Haemolytic Events in Controlled Trials with G6PD Screening

    by Ayleen Kosasih, Robert James, Nguyen Hoang Chau, Michelle M. Karman, Lydia Visita Panggalo, Lyndes Wini, Ngo Viet Thanh, Thomas Obadia, Ari Winasti Satyagraha, Puji Budi Setia Asih, et al.

    Primaquine for radical cure of Plasmodium vivax malaria poses a potentially life-threatening risk of haemolysis in G6PD-deficient patients. Herein, we review five events of acute haemolytic anaemia following the administration of primaquine in four malaria trials from Indonesia, the Solomon Islands, and Vietnam. Five males aged 9 to 48 years were improperly classified as G6PD-normal by various screening procedures and included as subjects in trials of anti-relapse therapy with daily primaquine. Routine safety monitoring by physical examination, urine inspection, and blood haemoglobin (Hb) assessment were performed in all those trials. Early signs of acute haemolysis, i.e., dark urine and haemoglobin drop >20%, occurred only after day 3 and as late as day 8 of primaquine dosing. All patients were hospitalized and fully recovered, all but one following blood transfusion rescue. Hb nadir was 4.7 to 7.9 g/dL. Hospitalization was for 1 to 7 days. Hb levels returned to baseline values 3 to 10 days after transfusion. Failed G6PD screening procedures in these trials led G6PD-deficient patients to suffer harmful exposures to primaquine. The safe application of primaquine anti-relapse therapy requires G6PD screening and anticipation of its failure with a means of prompt detection and rescue from the typically abrupt haemolytic crisis.


  • Open Access

    Genetic Variants of Glucose-6-Phosphate Dehydrogenase and Their Associated Enzyme Activity: A Systematic Review and Meta-Analysis

    by Daniel A. Pfeffer, Ari Winasti Satyagraha, Arkasha Sadhewa, Mohammad Shafiul Alam, Germana Bancone, Yap Boum, Marcelo Brito, Liwang Cui, Zeshuai Deng, Gonzalo J. Domingo, et al.

    Low glucose-6-phosphate dehydrogenase enzyme (G6PD) activity is a key determinant of drug-induced haemolysis. More than 230 clinically relevant genetic variants have been described. We investigated the variation in G6PD activity within and between different genetic variants. In this systematic review, individual patient data from studies reporting G6PD activity measured by spectrophotometry and corresponding the G6PD genotype were pooled (PROSPERO: CRD42020207448). G6PD activity was converted into percent normal activity applying study-specific definitions of 100%. In total, 4320 individuals from 17 studies across 10 countries were included, where 1738 (40.2%) had one of the 24 confirmed G6PD mutations, and 61 observations (3.5%) were identified as outliers. The median activity of the hemi-/homozygotes with A-(c.202G>A/c.376A>G) was 29.0% (range: 1.7% to 76.6%), 10.2% (range: 0.0% to 32.5%) for Mahidol, 16.9% (range 3.3% to 21.3%) for Mediterranean, 9.0% (range: 2.9% to 23.2%) for Vanua Lava, and 7.5% (range: 0.0% to 18.3%) for Viangchan. The median activity in heterozygotes was 72.1% (range: 16.4% to 127.1%) for A-(c.202G>A/c.376A>G), 54.5% (range: 0.0% to 112.8%) for Mahidol, 37.9% (range: 20.7% to 80.5%) for Mediterranean, 53.8% (range: 10.9% to 82.5%) for Vanua Lava, and 52.3% (range: 4.8% to 78.6%) for Viangchan. A total of 99.5% of hemi/homozygotes with the Mahidol mutation and 100% of those with the Mediterranean, Vanua Lava, and Viangchan mutations had A/c.376A>G), 55% of hemi/homozygotes had <30% activity. The G6PD activity for each variant spanned the current classification thresholds used to define clinically relevant categories of enzymatic deficiency.


  • Open Access

    Variation in Glucose-6-Phosphate Dehydrogenase activity following acute malaria

    by Benedikt Ley, Mohammad Shafiul Alam, Ari Winasti Satyagraha, Ching Swe Phru, Kamala Thriemer, Dagimawie Tadesse, Tamiru Shibiru, Asrat Hailu, Mohammad Golam Kibria, Mohammad Sharif Hossain, et al.

    Primaquine and tafenoquine are the only licensed drugs with activity against Plasmodium vivax hypnozoites but cause haemolysis in patients with glucose–6–phosphate dehydrogenase (G6PD) deficiency. Malaria also causes haemolysis, leading to the replacement of older erythrocytes with low G6PD activity by reticulocytes and young erythrocytes with higher activity. Aim of this study was to assess the impact of acute malaria on G6PD activity. Selected patients with uncomplicated malaria were recruited in Bangladesh (n = 87), Indonesia (n = 75), and Ethiopia (n = 173); G6PD activity was measured at the initial presentation with malaria and a median of 176 days later (range 140 to 998) in the absence of malaria. Among selected participants (deficient participants preferentially enrolled in Bangladesh but not at other sites) G6PD activity fell between malaria and follow up by 79.1% (95%CI: 40.4 to 117.8) in 6 participants classified as deficient (P. vivax or P. falciparum infection. Overall, 66.7% (4/6) severely deficient participants and 87.2% (34/39) with intermediate deficiency had normal activities when presenting with malaria. These findings suggest that G6PD activity rises significantly and at clinically relevant levels during acute malaria. Prospective case-control studies are warranted to confirm the degree to which the predicted population attributable risks of drug induced haemolysis is lower than would be predicted from cross sectional surveys.


  • Open Access

    Repeatability and reproducibility of a handheld quantitative G6PD diagnostic

    by Benedikt Ley, Ari Winasti Satyagraha, Mohammad Golam Kibria, Jillian Armstrong, Germana Bancone, Amy K. Bei, Greg Bizilj, Marcelo Brito, Xavier C. Ding, Gonzalo J. Domingo, et al.

    Background: The introduction of novel short course treatment regimens for the radical cure of Plasmodium vivax requires reliable point-of-care diagnosis that can identify glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. While deficient males can be identified using a qualitative diagnostic test, the genetic make-up of females requires a quantitative measurement. SD Biosensor (Republic of Korea) has developed a handheld quantitative G6PD diagnostic (STANDARD G6PD test), that has approximately 90% accuracy in field studies for identifying individuals with intermediate or severe deficiency. The device can only be considered for routine care if precision of the assay is high. Methods and findings: Commercial lyophilised controls (ACS Analytics, USA) with high, intermediate, and low G6PD activities were assessed 20 times on 10 Biosensor devices and compared to spectrophotometry (Pointe Scientific, USA). Each device was then dispatched to one of 10 different laboratories with a standard set of the controls. Each control was tested 40 times at each laboratory by a single user and compared to spectrophotometry results. When tested at one site, the mean coefficient of variation (CV) was 0.111, 0.172 and 0.260 for high, intermediate, and low controls across all devices respectively; combined G6PD Biosensor readings correlated well with spectrophotometry (rs = 0.859, ps = 0.604, p<0.001) and G6PD activity determined by Biosensor for the low and intermediate controls overlapped. The use of lyophilised human blood samples rather than fresh blood may have affected these findings. Biosensor G6PD readings between sites did not differ significantly (p = 0.436), whereas spectrophotometry readings differed markedly between sites (p<0.001). Conclusions: Repeatability and inter-laboratory reproducibility of the Biosensor were good; though the device did not reliably discriminate between intermediate and low G6PD activities of the lyophilized specimens. Clinical studies are now required to assess the devices performance in practice.


  • Open Access

    Genotypes and phenotypes of G6PD deficiency among Indonesian females across diagnostic thresholds of G6PD activity guiding safe primaquine therapy of latent malaria

    by Ari Winasti Satyagraha, Arkasha Sadhewa, Lydia Visita Panggalo, Decy Subekti, Iqbal Elyazar, Saraswati Soebianto, Nunung Mahpud, Alida Rosita Harahap, J. Kevin Baird

    Background: Plasmodium vivax occurs as a latent infection of liver and a patent infection of red blood cells. Radical cure requires both blood schizontocidal and hypnozoitocidal chemotherapies. The hypnozoitocidal therapies available are primaquine and tafenoquine, 8-aminoquinoline drugs that can provoke threatening acute hemolytic anemia in patients having an X-linked G6PD-deficiency. Heterozygous females may screen as G6PD-normal prior to radical cure and go on to experience hemolytic crisis. Methods & findings: This study examined G6PD phenotypes in 1928 female subjects living in malarious Sumba Island in eastern Indonesia to ascertain the prevalence of females vulnerable to diagnostic misclassification as G6PD-normal. All 367 (19%) females having P. vivax may leave one in ten females at risk of hemolytic crisis, which may be remedied by point-of-care quantitative tests.